SCHEMBL200965

SCHEMBL200965

COC(=O)C(NC(=O)c1ccc(-c2ccsc2)cc1)C(F)(F)F

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 3/20 0.43
HDAC6 Q9UBN7 2/20 0.43
MMP2 P08253 1/20 0.40
MMP9 P14780 1/20 0.40
MMP8 P22894 1/20 0.40
MLYCD O95822 1/20 0.40
CHEK2 O96017 2/20 0.39
DRD3 P35462 5/20 0.39
CTSL P07711 1/20 0.39
CTSB P07858 1/20 0.39
CTSS P25774 1/20 0.39
CTSK P43235 1/20 0.39
P2RY14 Q15391 1/20 0.38
GPR119 Q8TDV5 1/20 0.38
DRD2 P14416 3/20 0.37
HDAC4 P56524 1/20 0.37
MAP3K5 Q99683 1/20 0.36
TACR3 P29371 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL202862 0.84 DRD3 (0.39) HDAC1HDAC6CHEK2DRD3CTSL
SCHEMBL201903 0.80 ANPEP (0.41) HDAC1HDAC6MLYCDCTSLCTSS
SCHEMBL202434 0.78 TAS1R3 (0.57) MMP2MLYCDCTSS
SCHEMBL203558 0.78 RAB9A (0.54)
SCHEMBL13266878 0.71 KMT2A (0.55) HDAC1HDAC6HDAC4
SCHEMBL5944164 0.70 HDAC1 (0.63) HDAC1HDAC6MMP2MMP9MMP8
SCHEMBL5079391 0.70 GRIA4 (0.49) HDAC1HDAC6CTSLCTSBCTSS
SCHEMBL28905896 0.70 HDAC1 (0.46) HDAC1HDAC6CTSLCTSBCTSS
SCHEMBL254376 0.69 CA2 (0.43) HDAC1MLYCD
SCHEMBL21082225 0.68 ALDH1A1 (0.47) MMP2MMP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088804-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2012-01-03 US disclosed
EP-2338878-A2 N-hydroxyamide derivatives possessing antibacterial activity Vicuron Pharmaceuticals, Inc. (US) 2011-06-29 EP disclosed
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. 2010-01-28 US disclosed
EP-1963262-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2008-09-03 EP disclosed
WO-2007069020-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY NAAA, HDHD5, HACL2 HDAC1 404/4885HDAC6 306/4885MMP2 1855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.